GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Cyclically Adjusted Price-to-FCF

AbbVie (WBO:ABBV) Cyclically Adjusted Price-to-FCF : 16.99 (As of May. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is AbbVie Cyclically Adjusted Price-to-FCF?

As of today (2024-05-14), AbbVie's current share price is €148.62. AbbVie's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €8.75. AbbVie's Cyclically Adjusted Price-to-FCF for today is 16.99.

The historical rank and industry rank for AbbVie's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

WBO:ABBV' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 15.05   Med: 18.39   Max: 23.97
Current: 16.98

During the past years, AbbVie's highest Cyclically Adjusted Price-to-FCF was 23.97. The lowest was 15.05. And the median was 18.39.

WBO:ABBV's Cyclically Adjusted Price-to-FCF is ranked better than
76.29% of 329 companies
in the Drug Manufacturers industry
Industry Median: 33.59 vs WBO:ABBV: 16.98

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AbbVie's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €1.996. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €8.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AbbVie Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AbbVie's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Cyclically Adjusted Price-to-FCF Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 18.76 19.53 19.55 16.63

AbbVie Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.65 15.26 16.23 16.63 19.17

Competitive Comparison of AbbVie's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted Price-to-FCF falls into.



AbbVie Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AbbVie's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=148.62/8.75
=16.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AbbVie's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.996/129.4194*129.4194
=1.996

Current CPI (Mar. 2024) = 129.4194.

AbbVie Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.721 100.560 0.928
201409 0.774 100.428 0.997
201412 -0.368 99.070 -0.481
201503 0.827 99.621 1.074
201506 0.937 100.684 1.204
201509 1.086 100.392 1.400
201512 1.016 99.792 1.318
201603 1.109 100.470 1.429
201606 0.975 101.688 1.241
201609 0.729 101.861 0.926
201612 0.832 101.863 1.057
201703 1.171 102.862 1.473
201706 1.044 103.349 1.307
201709 1.646 104.136 2.046
201712 1.264 104.011 1.573
201803 1.284 105.290 1.578
201806 1.499 106.317 1.825
201809 2.400 106.507 2.916
201812 1.914 105.998 2.337
201903 1.737 107.251 2.096
201906 1.401 108.070 1.678
201909 2.695 108.329 3.220
201912 1.884 108.420 2.249
202003 2.250 108.902 2.674
202006 1.570 108.767 1.868
202009 2.686 109.815 3.166
202012 2.112 109.897 2.487
202103 2.219 111.754 2.570
202106 2.194 114.631 2.477
202109 3.692 115.734 4.129
202112 2.430 117.630 2.674
202203 2.424 121.301 2.586
202206 2.590 125.017 2.681
202209 4.223 125.227 4.364
202212 3.824 125.222 3.952
202303 2.113 127.348 2.147
202306 3.201 128.729 3.218
202309 3.891 129.860 3.878
202312 2.348 129.419 2.348
202403 1.996 129.419 1.996

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AbbVie  (WBO:ABBV) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AbbVie Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AbbVie's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (WBO:ABBV) Business Description

Industry
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

AbbVie (WBO:ABBV) Headlines

From GuruFocus

Q4 2021 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc will Acquire ImmunoGen Inc M&A Call Transcript

By GuruFocus Research 01-22-2024

Q2 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024